Matti Poutanen
PhD
matpou@utu.fi +358 29 450 2632 +358 50 366 0140 Kiinamyllynkatu 10 Turku Office: C507 ORCID identifier: https://orcid.org/000-0002-8953-1734 |
gentically modified mice, sex steroids, endometriosis, hormonal cancer
EDUCATIONAL
TRAINING
1987, M.Sc., Department of Biochemistry, University of
Oulu, Finland
1993, Ph.D., Department of Clinical Chemistry,
University of Oulu, Finland
1997, Title of Docent
(Adjunct professor); Biochemical Endocrinology, University of Oulu, Finland
CURRENT
POSITIONS
Professor, Department of Physiology,
University of Turku, and Director of Turku Center for Disease Modeling,
University of Turku, Finland
Senior Scientist
lecturer, Institute of Medicine, The Sahlgrenska Academy, Gothenburg
University, Gothenburg, Sweden
MAJOR GRANTS:
Academy
of Finland, The Finnish Cancer Organisations, Sigrid Juselius Foundation, Novo
Foundation, Vetenskaps Rådet, Business Finland and Industry
SUPERVISION OF STUDENTS: 30 PhD students supervised, 6 in training.
SCIENTIFIC
AND SOCIETAL IMPACT OFD THE WORK
Research
is mainly focused on sex steroid synthesis and action, with total number of
citation 6270 (Web of Science, April 2018); number of citations in 2017: ~400;
average citations per article: 26.8; h-index: 46; 182 original peer-reviewed
publications; 5 publications in high-impact journals (I.F. ≥ 10): J. Clin. Invest. 2x (I.F. 13), Cell Metab.(I.F. 17), Nat. Med. (I.F.
28), Gut (I.F. 14)
Co-founder, Forendo
Pharma ltd (www.forendo.com) focusing on hormonal therapies for endometriosis
and male hypogonadism. The company has closed its investment rounds with the
leading Nordic start-up investors Karolinska Development AB, Novo Seeds and
Finnvera.
Our research group has been internationally in a key position in
providing evidence for the concept where the ligand concentration available for
steroid hormone receptor binding is markedly regulated by the target tissue
metabolism, termed intracrine steroid
hormone action. The concept has proven to be essential for the growth and
progression of both prostate and breast cancer. We, furthermore, have shown
this concept to be valid also in premenopausal women, eg. in the endometriosis,
and other medically relevant implications are expected to rise in the near
future.
Teaching experience in, endocrinology, developmental biology, hormonal cancer, GM mice and animal models and in vivo imaging
- Novel hydroxysteroid (17 β) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice (2010)
- American Journal of Pathology
(A1 Refereed original research article in a scientific journal) - Stromal Activation Associated with Development of Prostate Cancer in Prostate-Targeted Fibroblast Growth Factor 8b Transgenic Mice (2010)
- Neoplasia
(A1 Refereed original research article in a scientific journal) - In vivo mouse model for analysis of hydroxysteroid (17beta) dehydrogenase 1 inhibitors (2009)
- Molecular and Cellular Endocrinology
(A1 Refereed original research article in a scientific journal) - Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts (2009)
- British Journal of Cancer
(A1 Refereed original research article in a scientific journal) - The androgen and progesterone receptors regulate distinct gene networks and cellular functions in decidualizing endometrium (2008)
- Endocrinology
(A1 Refereed original research article in a scientific journal) - Activation of androgens by hydroxysteroid (17beta) dehydrogenase 1 in vivo as a cause of prenatal masculinization and ovarian benign serous cystadenomas (2007)
- Molecular Endocrinology -Baltimore-
(A1 Refereed original research article in a scientific journal) - Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme (2006)
- Molecular and Cellular Endocrinology
(A1 Refereed original research article in a scientific journal) - Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts (2006)
- Endocrinology
(A1 Refereed original research article in a scientific journal)
